Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma

被引：7

作者：

Vita, Emanuele ^{[1
,2
]}

Stefani, Alessio ^{[1
,2
]}

Di Salvatore, Mariantonietta ^{[1
,2
]}

Chiappetta, Marco ^{[3
]}

Lococo, Filippo ^{[3
]}

Margaritora, Stefano ^{[3
]}

Tortora, Giampaolo ^{[1
,2
]}

Bria, Emilio ^{[1
,2
]}

机构：

[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Comprehens Canc Ctr, I-00168 Rome, Italy

[2] Univ Cattolica Sacro Cuore, Med Oncol, Dipartimento Med & Chirurg Traslaz, I-00168 Rome, Italy

[3] Univ Cattolica Sacro Cuore, Thoracy Surg, Dipartimento Med & Chirurg Traslaz, I-00168 Rome, Italy

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 11期

关键词：

malignant pleural mesothelioma; immunotherapy; target therapy; ENDOTHELIAL GROWTH-FACTOR; GERMLINE BAP1 MUTATIONS; CELL-CYCLE ARREST; OPEN-LABEL; PHASE-II; SINGLE-ARM; DOUBLE-BLIND; CHEMOTHERAPY; MULTICENTER; 2ND-LINE;

D O I：

10.3390/jcm10112290

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by very poor prognosis and lack of treatment options. Immunotherapy has rapidly emerged as an effective tool for MPM, particularly for tumors of non-epithelioid histology. At the same time, comprehensive genomic sequencing may open the way to new-generation targeted-drugs able to hit specific MPM molecular vulnerabilities. These innovations will possibly enrich, but also dramatically complicate, the elucidation of treatment algorithms. Multidisciplinary integration is urgently needed.

引用

页数：13

共 70 条

[1] Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification [J].

Alay, Ania ;

Cordero, David ;

Hijazo-Pechero, Sara ;

Aliagas, Elisabet ;

Lopez-Doriga, Adriana ;

Marin, Raul ;

Palmero, Ramon ;

Llatjos, Roger ;

Escobar, Ignacio ;

Ramos, Ricard ;

Padrones, Susana ;

Moreno, Victor ;

Nadal, Ernest ;

Sole, Xavier .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)

[2] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].

Alley, Evan W. ;

Lopez, Juanita ;

Santoro, Armando ;

Morosky, Anne ;

Saraf, Sanatan ;

Piperdi, Bilal ;

van Brummelen, Emilie .

LANCET ONCOLOGY, 2017, 18 (05) :623-630

[3]

[Anonymous], ASS IT REG TUM

[4]

Aoe K., 2007, ANTICANCER RES, V26, P232

[5] Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro [J].

Baas, P. ;

Fennell, D. ;

Kerr, K. M. ;

Van Schil, P. E. ;

Haas, R. L. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2015, 26 :V31-V39

[6] First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial [J].

Baas, Paul ;

Scherpereel, Arnaud ;

Nowak, Anna K. ;

Fujimoto, Nobukazu ;

Peters, Solange ;

Tsao, Anne S. ;

Mansfield, Aaron S. ;

Popat, Sanjay ;

Jahan, Thierry ;

Antonia, Scott ;

Oulkhouir, Youssef ;

Bautista, Yolanda ;

Cornelissen, Robin ;

Greillier, Laurent ;

Grossi, Francesco ;

Kowalski, Dariusz ;

Rodriguez-Cid, Jeronimo ;

Aanur, Praveen ;

Oukessou, Abderrahim ;

Baudelet, Christine ;

Zalcman, Gerard .

LANCET, 2021, 397 (10272) :375-386

[7] Inference on Germline BAP1 Mutations and Asbestos Exposure from the Analysis of Familial and Sporadic Mesothelioma in a High-Risk Area [J].

Betti, Marta ;

Casalone, Elisabetta ;

Ferrante, Daniela ;

Romanelli, Antonio ;

Grosso, Federica ;

Guarrera, Simonetta ;

Righi, Luisella ;

Vatrano, Simona ;

Pelosi, Giuseppe ;

Libener, Roberta ;

Mirabelli, Dario ;

Boldorini, Renzo ;

Casadio, Caterina ;

Papotti, Mauro ;

Matullo, Giuseppe ;

Magnani, Corrado ;

Dianzani, Irma .

GENES CHROMOSOMES & CANCER, 2015, 54 (01) :51-62

[8] Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations [J].

Bueno, Raphael ;

Stawiski, Eric W. ;

Goldstein, Leonard D. ;

Durinck, Steffen ;

De Rienzo, Assunta ;

Modrusan, Zora ;

Gnad, Florian ;

Nguyen, Thong T. ;

Jaiswal, Bijay S. ;

Chirieac, Lucian R. ;

Sciaranghella, Daniele ;

Dao, Nhien ;

Gustafson, Corinne E. ;

Munir, Kiara J. ;

Hackney, Jason A. ;

Chaudhuri, Amitabha ;

Gupta, Ravi ;

Guillory, Joseph ;

Toy, Karen ;

Ha, Connie ;

Chen, Ying-Jiun ;

Stinson, Jeremy ;

Chaudhuri, Subhra ;

Zhang, Na ;

Wu, Thomas D. ;

Sugarbaker, David J. ;

de Sauvage, Frederic J. ;

Richards, William G. ;

Seshagiri, Somasekar .

NATURE GENETICS, 2016, 48 (04) :407-+

[9] Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study [J].

Calabro, Luana ;

Morra, Aldo ;

Giannarelli, Diana ;

Amato, Giovanni ;

D'Incecco, Armida ;

Covre, Alessia ;

Lewis, Arthur ;

Rebelatto, Marlon C. ;

Danielli, Riccardo ;

Altomonte, Maresa ;

Di Giacomo, Anna Maria ;

Maio, Michele .

LANCET RESPIRATORY MEDICINE, 2018, 6 (06) :451-460

[10] Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study [J].

Calabro, Luana ;

Morra, Aldo ;

Fonsatti, Ester ;

Cutaia, Omella ;

Fazio, Carolina ;

Annesi, Diego ;

Lenoci, Marica ;

Amato, Giovanni ;

Danielli, Riccardo ;

Altomonte, Maresa ;

Giannarelli, Diana ;

Di Giacomo, Anna Maria ;

Maio, Michele .

LANCET RESPIRATORY MEDICINE, 2015, 3 (04) :301-309

← 1 2 3 4 5 6 7 →